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Abstract
The role of high-density lipoprotein (HDL) function and advanced glycation end products (AGEs) in HIV-related atherosclerotic
cardiovascular disease (CVD) is unclear. Both glycation and oxidation (HDLox) are major modifications of HDL that can alter its
composition and function. Therefore, we explored the longitudinal association of HDLox with progression of glycation, as evaluated by
measurement of circulating forms of receptor for AGE that predict morbidity (soluble Receptors for Advanced Glycation Endproducts
[sRAGE], endogenous secretory Receptors for AdvancedGlycation Endproducts [esRAGE]), in people with HIV-1 (PWH; HIV-1+) and
uninfected (HIV-1) individuals.
We retrospectively assessed if levels of plasma sRAGE and esRAGE and HDL function (reduced antioxidant function is associated
with increased HDL lipid hydroperoxide content; HDLox) in a subset of participants (n=80) from a prospective 3-year study (AIDS
Clinical Trials Group A5078). Primary outcomes were baseline and yearly rates of change over 96 of 144 weeks (D) in HDLox in HIV-1
+
versus uninfected HIV-1 controls (noted as HIV-1).
Higher baseline levels of sRAGE in PWH on effective anti-retroviral therapy and with low CVD risk, but not in HIV-1 persons, were
independently associated with higher HDLox. EsRAGE, but not sRAGE, had consistent inverse relationships withDHDLox in both HIV-
1+ and HIV-1 persons at baseline. In HIV-1 but not in HIV-1+ persons, DHDLox had positive and inverse relationships with DRAGE
and DesRAGE, respectively.
Glycation and oxidation of HDL may contribute to impaired HDL function present in PWH.
Abbreviations: DesRAGE = yearly rates of change over 96/144 weeks (D) in endogenous secretory receptors for advanced
glycation endproducts, DHDLox = yearly rates of change over 96/144 weeks (D) in oxidized high-density lipoprotein, DRAGE = yearly
rates of change over 96/144weeks (D) in receptors for advanced glycation endproducts, ACTG=AIDSClinical Trials Group, AGER=
the gene encoding Receptors for Advanced Glycation Endproducts (RAGE), AGEs = advanced glycation end products, AIDS =
acquired immune deficiency syndrome, ART= antiretroviral therapy, BMI= bodymass index, CD4= cluster of differentiation 4, CIMT
= carotid intima-media thickness, CVD = atherosclerotic cardiovascular disease, DHR = dihydrorhodamine 123, ELISA = enzyme-
linked immunosorbent assay, esRAGE = endogenous secretory receptors for advanced glycation endproducts, FU = fluorescence
units, HBS = N-2-hydroxyethylpiperazine-N’-2-ethanesulfonic acid buffered saline, HDL = high-density lipoprotein, HDLox =
oxidized high-density lipoprotein, HEPES = N-2-hydroxyethylpiperazine-N’-2-ethanesulfonic acid, HIV-1- = seronegative people not
infected with human immunodeficiency virus 1, HIV-1+ = seropositive people infected with human immunodeficiency virus 1, HIV-
HDL = high-density lipoprotein in chronic, treated HIV infection, hs-CRP = high-sensitivity C-reactive protein, LDL = low-density
lipoprotein, MDFCM = monocyte-derived foam cell formation, Min = Minute, MMPs = matrix metalloproteinases, PI = ProteaseEditor: Akhilanand Chaurasia.
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inhibitor therapy, PWH = people with HIV-1, RNA = ribonucleic acid, sRAGE = soluble receptors for advanced glycation
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Despite potent antiretroviral therapy, people with chronic HIV-1
infection (PWH) have increased risk of atherosclerotic cardio-
vascular disease (CVD), but the mechanisms are unclear.[1] High-
density lipoprotein cholesterol (HDL-C) function, rather than
absolute level, may more accurately predict atherosclerosis.[1] In
HIV-seronegative (HIV-1) persons, abnormal HDL function
strongly correlates with clinical CVD.[2] Inflammatory states such
as chronic HIV-1 infection can induce protein and lipid
compositional changes that impair HDL function, reduce anti-
inflammatory and antioxidant proteins, and increase HDL lipid
hydroperoxide content and redox activity (HDLox).
[3]
Glycation is a major modification of HDL that can alter its
composition and function.[4–6] Under aerobic conditions,
glycation and oxidation interact to form glycoxidation, or
advanced glycation end products (AGEs), on proteins and lipids.
Numerous studies suggest that circulating levels of soluble
Receptors for Advanced Glycation Endproducts (RAGE) that
bind to and transduce the signal stimulated by AGEs are
implicated in the pathogenesis of chronic diseases such as
diabetes and atherosclerosis.[7,8] In humans, 2 soluble forms of
RAGE are detectable, including soluble (sRAGE, a form of the
extracellular receptor cleaved from the cell surface via the actions
of various proteases such as matrix metalloproteinases [MMPs]
that are also regulated by oxidized lipoproteins[9]) and endoge-
nous secretory (esRAGE, the translation product of a splice
variant of AGER, the gene encoding RAGE).[7] We have
previously shown that RAGE suppresses macrophage cholesterol
efflux in diabetes,[10] and dysfunctional HDL from PWH with
low CVD risk promotes monocyte-derived foam cell formation
(MDFCM) in vitro.[11] However, little is known about the role of
RAGE, HDL function, and the cross-talk between glycation and
HDL function in chronic treated HIV-1 infection.
NWCS332 was a sub-study of AIDS Clinical Trials Group
(ACTG) A5078, which was designed to study the role of protease
inhibitor (PI) therapy and HIV infection on the risk of
development of subclinical atherosclerosis (as evaluated by
carotid intima-media thickness, CIMT) and its progression.[12] In
NWCS332, we previously reported that serum HDLox (assessed
by a biochemical assay that quantifies the antioxidant function of
HDL; higher HDLox indicates HDL dysfunction
[13]) declined
over 3 years but was not associated with progression of
CIMT;[14] baseline (e)sRAGE levels were not significantly
different between the HIV-1+ and HIV-1 groups;[15] there were
positive yearly rates of change in sRAGE within the HIV-1+
group and in esRAGEwithin both groups;[15] and increased odds
of CIMT progression were associated with lower baseline
esRAGE in HIV-1+ group.[15]
Although both oxidation and glycation are modifications
of HDL that may underlie some of the atherogenic properties
of impaired HDL, it is unknown whether complex
interactions between glycation and HDL may underlie some
of the atherogenic properties of HIV-HDL. The overall goal of
this sub-study was to investigate a role for (e)sRAGE as
biomarkers and/or mediators of HDL function in PWH and as2a possible driver of atherosclerotic risk in chronic, treated HIV
infection.
Our objectives were to be the first to explore the longitudinal
association of HDLox with changes in glycation, as evaluated by
measurement of circulating forms of receptors for glycation
products that predict morbidity (sRAGE, esRAGE), in HIV-1+
and HIV-1 individuals using data from NWCS332. We
hypothesized that with chronic inflammation resulting from
HIV-1 infection, sRAGE and esRAGE would increase over
time[16] in association with higher HDLox.
2. Methods
2.1. Study design and participants
The present study is a subset analysis of samples obtained from a
prospective,matched cohort study[14,15] inwhichparticipantswere
enrolled as risk factor-matched triads of HIV-1+ individuals with
HIV-1viremia<500RNAcopies/mLwith (n=29) orwithout (n=
26) use of PI therapy, and HIV-1-uninfected individuals (n=36)
from 41 triads. Individuals were excluded if they had diabetes
mellitus, family history of early myocardial infarction in first-
degree relatives, a history of coronary heart disease or stroke,
uncontrolled hypertension, untreated hypothyroidism, or obesity.
Individuals requiring systemic chemotherapy, radiation therapy,
or systemic steroids were also excluded, as were individuals with a
serum creatinine >1.5mg/dL or alanine or aspartate amino-
transferases >2.5 upper limit of normal. Individuals were
excluded from NWCS332 if they had HIV RNA ≥500copies/mL
or missing stored samples (weeks 0, 72, and 144 (or week 96 if
week 144wasmissing; thus, “week 96/144”). The 80 participants
who had the required HIV-1 RNA level and sufficient residual
sample tobe included in this analysiswere from40 triads (Group1:
n=25, Group 2: n=21, and Group 3: n=34), of which 9 triads
were complete. Given thatwe did not find notable differences in (e)
sRAGE among the 2HIV groups (with orwithout PIs),[15] theHIV
groups were combined. The A5078 informed consent document
included the provision for future testing of stored samples for
ACTG-approved AIDS-related research and the study was
approved by the local institutional review boards.
2.2. Data collection
Clinical data, CVD-related measurements, (e)sRAGE, andHDLox
have previously been described.[14,15] Fasting glucose, insulin,
lipids, cardiovascular/metabolic disease-related measurements
(including homocysteine and high-sensitivity C-reactive protein
[hs-CRP]),CD4+cell counts, andHIV-1RNAlevelswere collected
at A5078 study entry. In this secondary analysis utilizing stored
A5078 samples, levels of plasma sRAGE and esRAGE were
measured at weeks 0, 72, and 96/144 in individuals who also had
HIV RNA <500copies/mL and CIMT results at all time points.
2.3. Determination of sRAGE and esRAGE
In this study, plasma sRAGE and esRAGE levels were assayed on
stored samples using enzyme-linked immunosorbent assay
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(R&D Systems Quantikine ImmunoassayMinneapolis, MN; and
B-Bridge ELISA, B-Bridge International, Cupertino, CA). Stored
samples from baseline, week 72, and week 144 (or 96 if week 144
was missing) were assayed.2.4. Reagents
Dihydrorhodamine 123 (DHR) was obtained from Molecular
Probes (Eugene, OR). DHR was prepared as a stock of 50mmol/
L in dimethyl sulfoxide as previously described.[14] Iron-free N-2-
hydroxyethylpiperazine-N’-2-ethanesulfonic acid (HEPES)-buff-
ered saline (HBS, HEPES 20mmol/L, NaCl 150mM, pH 7.4) was
prepared as previously described.[14] The DHR stock was diluted
1:1000 inHEPES saline solution to prepare a working solution of
50mmol/L.2.5. HDL purification
HDL was isolated using precipitation with polyethylene glycol
and ultracentrifugation, aliquoted, and stored as previously
described. HDL cholesterol was quantified using a standard
colorimetric assay (Thermo DMA Co., San Jose, CA) as
previously described.[14]2.6. Biochemical cell-free assay of HDL function
Quadruplicates of HDL (2.5mg of cholesterol unless otherwise
specified) were added to 96-well plates (polypropylene, flat
bottom, black, Fisher Scientific). HBS was added to each well to a
final volume of 150mL, followed by addition of 25mL of the 50m
mol/L DHRworking solution, for a total volume of 175mL (final
DHR concentration of 7mmol/L). Immediately following DHR
addition, the plate was protected from light and placed in the
fluorescence plate reader (at 37°C). The fluorescence of each well
was assessed at 2-minute intervals during an hour with a Synergy
2 Multi-Mode Microplate Reader (Biotek, Winooski, VT), using
a 485/538nm excitation/emission filter pair with the photo-
multiplier sensitivity set at medium. Determination of oxidation
rate of DHR and the slope of oxidation of HDL (HDLox) was
performed by measuring the slope of fluorescence increase during
50 minutes after addition of a specific amount of lipid (HDL) as
previously described.[14] HDL oxidative function was calculated
as the mean of quadruplicates for the wells containing the HDL
sample.2.7. Statistical methods
Using SAS version 9.4 with SAS/STAT version 14.1, by-group
comparisons of baseline characteristics were assessed using Fisher
exact and Wilcoxon tests as appropriate. Spearman rank
correlation evaluated correlations. Mixed models regression
analyses evaluated whether baseline measurements of HDLox
were associated with baseline (e)sRAGE. Repeated measures
regression analyses evaluated associations between yearly rates of
change over 96/144 weeks (D) in HDLox and (e)sRAGE.
Regression models were fit within the HIV-1+ and HIV-1
groups separately. Mixed models regression analyses with triad
as a random effect evaluated whether baseline (week 0)
measurements of sRAGE and esRAGE were associated with
baseline HDLox. Repeated measures regression analyses with
triad as a random effect evaluated associations with yearly rates
of change over 144 weeks (or 96 weeks if the week 144 sample3was missing) in sRAGE, esRAGE, and HDLox. The baseline
covariates considered in the univariable analyses were age, sex,
race, fasting glucose, fasting lipid measurements (total cholester-
ol, low-density lipoprotein [LDL] cholesterol, and triglycerides],
use of lipid-lowering drugs, use of statins, body mass index
[BMI], waist circumference, waist/hip ratio, insulin, hs-CRP, and
homocysteine. For the HIV-1+, additional covariates included
CD4+ cell count and HIV RNA. The unadjusted associations of
the above covariates with HDLox, sRAGE, and esRAGE were
previously described.[15] Here, the univariable associations
between sRAGE and esRAGE (predictors) and baseline HDLox
and yearly rate of change in HDLox over 96/144 weeks
(outcomes) were adjusted for baseline HDL cholesterol and, in
the yearly rate of change analysis, also week 96/144 HDL. The
multivariable analysis was adjusted for baseline age, sex, HDL
cholesterol, glucose, and, for the HIV-1+, CD4+ cell count and
HIV RNA; the yearly rate in change analyses was also adjusted
for HDL cholesterol, CD4+, and HIV RNA at week 96/144.
Covariates with P< .20 in the univariable analysis were
examined together in multivariable analysis and reduced using
the backward elimination method, with the final multivariable
model containing covariates with P< .05. Results with 2-sided
P< .05 were deemed significant; no adjustments were made for
multiple comparisons.3. Results
3.1. Baseline characteristics
Participant characteristics are summarized in Table 1. The
participants were 91% male, 75% white/non-Hispanic, with a
median age of 41 years. The 46HIV-1+ had significantly (P< .05)
higher waist-to-hip ratio, more use of lipid lowering drugs, and
lower homocysteine levels compared to the HIV-1 participants.
Owing to matching, the groups were similar with respect to age,
sex, and race. As previously published, baseline HDLox and (e)
sRAGE levels were not significantly different between the groups
(P> .2).[14,15] Median baseline levels of HDLox, sRAGE, and
esRAGE were 243,753FU/min, 1039pg/mL, and 233pg/mL,
respectively.3.2. Baseline relationships between HDL function and (e)
sRAGE
Baseline HDLox was correlated with baseline esRAGE overall
and in HIV-1+ participants (Fig. 1). However, in the more robust
univariable regression analysis in PWH, baseline HDLox was
marginally associated with esRAGE (P= .051), but significantly
associated with sRAGE (P= .039; Table 2). In an adjusted
multivariable regression analysis in HIV-1+ participants, baseline
HDLox was marginally associated with baseline sRAGE (P
= .056) (Table 3). Assuming fixed levels of the covariates used to
adjust the model (details provided in Table 3), an increase in
baseline sRAGE by 100pg/mL (∼10% of median baseline level)
in HIV-1+ participants would result in, on average, an increase in
baseline HDLox by 0.55 per 10,000FU/min (∼2% of median
baseline level).
3.3. Relationships between changes in HDL function and
(e)sRAGE
As previously published, longitudinal levels of HDLox and (e)
sRAGE were not significantly different between the groups
[14,15] 
Table 1
Participant’ characteristics. Except otherwise indicated, data represent N (%) of participants.
Group
Total (N=80) HIV-uninfected (N=34) HIV-infected (N=46) P
Sex Male 73 (91%) 30 (88%) 43 (93%) .451
∗
Female 7 (9%) 4 (12%) 3 (7%)
Race/ethnicity White Non-Hispanic 60 (75%) 25 (74%) 35 (76%) .659
∗
Hispanic (regardless of race) 15 (19%) 8 (24%) 7 (15%)
Asian, Pacific Islander 3 (4%) 1 (3%) 2 (4%)
Other/unknown 2 (3%) 0 (0%) 2 (4%)
Age, y Median (Q1, Q3) 41 (36, 45) 40 (36, 45) 41 (37, 45) .949†
Glucose, mg/dL Median (Q1, Q3) 86 (79, 93) 85.5 (75, 92) 86 (81, 94) .335†
Total Cholesterol, mg/dL Median (Q1, Q3) 195 (162, 231) 184 (163, 206) 202 (159, 240) .261†
LDL cholesterol, mg/dL # Missing 2 0 2 .691†
Median (Q1, Q3) 115.5 (90, 149) 114 (88, 149) 116 (95.5, 150.5)
HDL cholesterol, mg/dL Median (Q1, Q3) 42 (35, 48.5) 43 (38, 50) 41 (35, 48) .566†
Triglycerides, mg/dL Median (Q1, Q3) 128 (91.5, 199) 112 (89, 153) 142.5 (96, 221) .068†
Use of lipid-lowering drugs None 70 (88%) 34 (100%) 36 (78%) .004
∗
Any 10 (13%) 0 (0%) 10 (22%)
Use of statins None 73 (91%) 34 (100%) 39 (85%) .019
∗
Any 7 (9%) 0 (0%) 7 (15%)
Body mass index, kg/m2 Median (Q1, Q3) 24.7 (23.4, 27.2) 24.8 (23.7, 27.7) 24.0 (23.4, 26.8) .690†
Waist circumference ≥90cm 43 (54%) 19 (56%) 24 (52%) >.999
∗
<90cm 36 (45%) 15 (44%) 21 (46%)
Missing 1 (1%) 0 (0%) 1 (2%)
Waist/hip ratio # Missing 1 0 1 .008†
Median (Q1, Q3) 0.90 (0.85, 0.93) 0.89 (0.83, 0.92) 0.92 (0.88, 0.94)
Insulin, mU/L # Missing 6 3 3 .300†
Median (Q1, Q3) 6.35 (5.1, 8.0) 6.1 (5.0, 7.7) 6.50 (5.5, 10.4)
Homocysteine, mmol/L # Missing 6 3 3 .018†
Median (Q1, Q3) 8.95 (7.4, 10.1) 9.7 (8.7, 11.0) 8.1 (6.8, 10.0)
hs-CRP, mg/L # Missing 6 3 3 .184†
Median (Q1, Q3) 1.0 (0.5, 2.1) 0.9 (0.5, 1.7) 1.1 (0.5, 3.3)
HIV-1 RNA <50 copies/mL — — 38 (83%) —
≥50 copies/mL — — 8 (17%) —
CD4, cells/mm3 Median (Q1, Q3) — — 514 (344, 679) —
Duration of ART, wk Median (Q1, Q3) — — 175 (124, 269) —
Ritonavir use None — — 34 (74%) —
Any — — 11 (24%) —
Missing — — 1 (2%) —
NRTI use None — — 1 (2%) —
Any — — 44 (96%) —
Missing — — 1 (2%) —
NNRTI use None — — 20 (43%) —
Any — — 25 (54%) —
Missing — — 1 (2%) —
HDLox, FU/min Median (Q1, Q3) 243,753 (202,048, 280,312) 236,089 (192,379, 270,475) 248,455 (212,56, 280,859) .274
†
sRAGE, pg/mL Median (Q1, Q3) 1039 (797, 1298) 1030 (797, 1265) 1064 (792, 1433) .517†
esRAGE, pg/mL Median (Q1, Q3) 233 (139, 337) 236 (128, 343) 229 (143, 331) .778†
ART=antiretroviral therapy, esRAGE=endogenous secretory receptors for advanced glycation endproducts, HDL=high-density lipoprotein, HDLox=oxidized high-density lipoprotein, hs-CRP=high-sensitivity
C-reactive protein, LDL= low-density lipoprotein, NNRTIs=Non Nucleoside Reverse Transcriptase Inhibitors, sRAGE= soluble receptors for advanced glycation endproducts.
∗
Fisher exact test.
†Wilcoxon test.
Kelesidis et al. Medicine (2018) 97:22 Medicine(P> .2). In univariable regression analysis, DHDLox was
significantly associated with baseline esRAGE (P< .05), but not
baseline sRAGE (P> .1; Table 2) in both groups. In the adjusted
multivariable regression analysis in HIV-1+ participants, positive
DHDLox was associated with lower baseline esRAGE (P= .012),
white race (P= .031) and lower baseline BMI (P< .001) (Table 3).
Assuming fixed levels of the other covariates in the model, a
decrease in baseline esRAGE by 100pg/mL (∼43% of median
baseline level) in HIV-1+ participants would result in, on average,
an increase in HDLox by 0.37 per 10,000FU/min/year (∼1.5% of
median baseline level). In the adjusted multivariable regression4analysis HIV-1 persons, positive DHDLox was significantly
associated with positive DsRAGE (P< .001), negative DesRAGE
(P< .001), and waist circumference ≥90cm (P= .003). Assuming
fixed levels of the other covariates in the model, including
DesRAGE and DsRAGE as applicable, for every 100pg/mL
increase in sRAGE over time (∼10% of median baseline level),
HDLox would, on average, increase by 0.26 per 10,000FU/min/
year (∼1% of median baseline level) or for every 100pg/mL
decrease in esRAGE over time (∼43% of median baseline level),
HDLox would, on average, increase by 0.10 per 10,000FU/min/
year (∼0.5% of median baseline level), respectively.
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Figure 1. Spearman rank correlations between baseline levels of HDLox, sRAGE (A, C) and esRAGE (B, D) between HIV-1
+ (A, B) and HIV-1 (C, D) participants.
Baseline HDLox was correlated with baseline esRAGE (Spearman rank r=0.274, P= .014) and remained correlated in the HIV-1+ group (P= .046). esRAGE=
endogenous secretory receptors for advanced glycation endproducts, HDLox=oxidized high-density lipoprotein, sRAGE=soluble receptors for advanced
glycation endproducts.
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In this exploratory sub-study of PWH with low CVD risk, we
found that higher baseline levels of the sRAGE biomarker of
glycation were associated with reduced baseline HDL antioxidantTable 2
Adjusted univariable associations of HDLox with sRAGE and esRAGE
HIV-1-infected p
Covariate Parameter estimate
Baseline HDLox (per 10,000 FU/min; per ∼5% of median baseline level)
Baseline sRAGE (per 100 pg/mL; per ∼10% change in
median baseline level)
0.477 (0.115, 0.8
Baseline esRAGE (per 100 pg/mL; per ∼43% change
in median level)
1.421 (0.265, 2.5
Yearly rate of change in HDLox (per 10,000 FU/min/year; per ∼5% change above median
Baseline sRAGE (per 100 pg/mL; per ∼10% change
above median baseline level per year)
0.080 (0.161, 0
Yearly rate of change in sRAGE (per 100 pg/mL/year;
per ∼10% change above median baseline level per
year)
0.060 (0.141, 0
Baseline esRAGE (per 100 pg/ml; per ∼43% change in
median level)
0.323 (0.563, 
Yearly rate of change in esRAGE (per 100 pg/mL/year;
per ∼43% change above median baseline level per
year)
0.051 (0.204, 0
White Race 1.626 (0.824, 2.4
BMI, kg/m2 0.148 (0.266, 
Waist circumference <90 cm –
BMI=body mass index, CI= confidence interval, esRAGE= endogenous secretory receptors for advanc
advanced glycation endproducts.
5function (higher HDLox). This association was not found in the
matched HIV-1 controls. EsRAGE, but not sRAGE, had
consistent inverse relationships with DHDLox in both PWH and
HIV-1 persons at baseline. These data complement our previous.
articipants (n=46) HIV-1-uninfected participants (n=34)
(95% CI) P Parameter estimate (95% CI) P
38) 0.039 0.008 (0.375, 0.358) 0.970
78) 0.051 0.724 (0.360, 1.810) 0.266
baseline level per year)
.002) 0.110 0.039 (0.135, 0.056) 0.492
.021) 0.221 0.319 (0.270, 0.367) 0.001
0.084) 0.028 0.332 (0.598, 0.066) 0.042
.101) 0.577 0.179 (0.245, 0.113) 0.001
29) 0.001 – –
0.030) 0.040 – –
– 1.475 (2.337, 0.614) 0.007
ed glycation endproducts, HDLox=oxidized high-density lipoprotein, sRAGE= soluble receptors for
Table 3
Adjusted multivariable associations of HDLox with sRAGE and esRAGE.
HIV-1-infected participants (n=46) HIV-1-uninfected participants (n=34)
Covariate Parameter estimate (95% CI) P Parameter estimate (95% CI) P
Baseline HDLox (per 10,000 FU/min; per ∼5% of median baseline level)
Baseline sRAGE (per 100 pg/mL; per ∼10% change in
median baseline level)
0.552 (0.020, 1.124) 0.056 – –
Baseline esRAGE (per 100 pg/mL; per ∼43% change in
median level)
– –
– –
Yearly rate of change in HDLox (per 10,000 FU/min/year; per ∼5% change above median baseline level per year)
Baseline sRAGE (per 100 pg/mL; per ∼10% change
above median baseline level per year)
– – – –
Yearly rate of change in sRAGE (per 100 pg/mL/year; per
∼10% change above median baseline level per year)
– – 0.259 (0.204, 0.614) 0.001
Baseline esRAGE (per 100 pg/mL; per ∼43% change in
median level)
0.374 (0.662, 0.086) 0.012 – –
Yearly rate of change in esRAGE (per 100 pg/mL/year;
per ∼43% change above median baseline level per
year)
– – 0.095 (2.587, 0.053) 0.001
White race 1.720 (0.168, 3.273) 0.031 – –
BMI, kg/m2 0.272 (0.415, 0.129) 0.001 – –
Waist circumference <90 cm – – 1.593 (2.587, 0.599) 0.003
BMI=body mass index, CI= confidence interval, esRAGE= endogenous secretory receptors for advanced glycation endproducts, HDLox=oxidized high-density lipoprotein, sRAGE= soluble receptors for
advanced glycation endproducts.
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DCIMT in chronic treated HIV-1 infection;[14,15] RAGE directly
contributes to atherogenic properties of macrophages;[10] HDL in
chronic, treated HIV infection (HIV-HDL) is dysfunctional and
oxidized even in PWHwith lowCVD risk;[14] andHIV-HDL from
PWH with low CVD risk promotes MDFCM in vitro.[11]
Collectively, these data suggest that complex interactions between
glycation and HDL may underlie some of the atherogenic
properties of HIV-HDL. This is the first longitudinal study
investigating a role for (e)sRAGE as biomarkers and/or mediators
ofHDLfunction inPWHandas a possible driver of atherosclerotic
risk in chronic, treated HIV infection. Elucidating the mechanisms
driving modifications of HDL and glycation may identify
dysfunctional HDL and glycation as potential therapeutic targets
to reduce HIV-related CVD risk.
In vitro studies indicate that oxidative modification of HDL
may impair cholesterol efflux activity. We showed that
dysfunctional HDL (higher HDLox) in PWH without clinical
CVD was associated with in vivo progression of CVD
(CIMT);[17] may stimulate endothelial cells to induce mono-
cyte/macrophage chemotaxis;[13,17] was positively correlated
with non-calcified coronary atherosclerotic plaque;[18] and was
independently correlatedwith severalmarkers of inflammation,
immune activation,[19] and with impaired HDL remodeling.[20]
Here we show that biomarkers of glycation are associated with
impaired HDL function, consistent with previous data about a
role of glycation in HDL dysfunction in diseases.[4,5] The
ligands of RAGE may interact with distinct non-RAGE
receptors, such as toll receptors that are also receptors for
(oxidized) lipoproteins. sRAGE is cleaved from the cell surface
via the actions of MMPs that are also regulated by oxidized
lipoproteins.[9] It is possible that higher HDL glycation may
lead to sequestration of esRAGE; alternatively, HDL glycation
may suppress the alternative splicing of RAGE and reduce levels
of esRAGE. The directionality of these complex interactions
depends on the inflammatory milieu and is probably specific to
diseases.[7,8,21–23]6In contrast to our study, the majority of previous studies
regarding RAGE were cross-sectional[24,25] and do not report
both sRAGE and esRAGE. Single time point analysis may not
take into account the effects of exacerbations of disease in
superimposed chronic diseases such as HIV. Consistent with this
hypothesis, sRAGE levels may change over time with disease
activity[16] and we found that higher baseline levels of esRAGE
were associated with higher baseline HDLox, but lower baseline
esRAGE levels were associated with positive DHDLox and lower
baseline esRAGE levels were associated with increased odds of
CIMT progression in the HIV-infected participants suggesting
that lower levels of soluble forms of esRAGEmay be a biomarker
of mechanisms that perpetuate vascular inflammation.[15]
The strengths of our study are the careful covariate
phenotyping of our study population, including novel measures
of HDL function and glycation. However, this study has several
limitations. The study population overall had a low risk for CVD,
which may have diminished our ability to study changes in levels
of (e)sRAGE and HDLox. All assays of HDL function have
limitations[26] and cholesterol efflux assays were not performed.
Other limitations are known with any biomarker[27] and also
include the small sample size and use of cryopreserved samples.
The clinical impact of measures of glycation and HDL function is
unknown.
In conclusion, our data provide important insight into the role
of glycation and dysfunctional HDLs as possible drivers of
increased atherosclerotic risk in this population. Because of the
role of RAGE and dysfunctional HDL in atherosclerosis,
diabetes, inflammation, and in view of the prevalence of CVD
in chronic treated HIV infection, further investigation of the
cross-talk between RAGE and dysfunctional HDL in the setting
of HIV is indicated.Acknowledgments
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